Engineering expert Elomatic has been chosen by FinVector for services on its new pharmaceutical facility in Finland.
Viral-based gene therapy product expert, FinVector, is expanding its production of bladder cancer medications with the construction of the new “GMP6” facility.
Elomatic told Cleanroom Technology that the cleanrooms for this new project will be 1,200 sqm and “site-built”.
GMP6 will manufacture viral vector drugs for bladder cancer. This is the same as the GMP5 facility, for which Elomatic also served as the project management consultant during 2023–2024.
The construction work will take place in the same building as the GMP5 facility. However, GMP6 is not merely a copy of its predecessor – its processes have been further developed to meet evolving production needs.
“Elomatic was a natural choice as a partner for this project. In addition to the GMP5 facility project, we have decades of successful collaboration with them, and we have strong confidence in their expertise,” said Tony Lönnbäck, Capital Project Director at FinVector.
GMP6
Elomatic will support FinVector with comprehensive project management, serving in a central advisory role.
The two companies signed an EPCM (Engineering, Procurement, and Construction Management) agreement on May 6, 2025.
Design work began at the end of 2023, and installation of the production areas will take place during 2025.
Elomatic explained to Cleanroom Technology that the cleanrooms in this production process are to be of Class C and D.
The facility is scheduled to be commissioned in early 2026, followed by a validation phase.
The design of the facility has focused not only on strict cleanliness and safety requirements but also on sustainability principles such as energy efficiency. Elomatic’s team includes a wide range of experts, from project management and design to procurement and quality.
“It is a great privilege to continue our collaboration with FinVector on such an impactful project. Being entrusted with the lead responsibility for the GMP6 facility is a significant vote of confidence and reinforces our position as a trusted partner in demanding facility projects,” said Mona Åkerholm, who leads Elomatic’s pharma unit.
Image credit: Elomatic